Pathogenetic communication of erectile dysfunction, anxiety and depressive disorders in hypertension

DOI: https://doi.org/10.29296/25877305-2018-07-17
Download full text PDF
Issue: 
7
Year: 
2018

Associate Professor E. Petrova(1), Candidate of Medical Sciences; Professor A. Shutov(2), MD; Professor V. Strukov(3), MD 1-Penza State University 2-Ulyanovsk State University 3-Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Academy of Continuing Professional Education

Erectile dysfunction (ED) in patients with arterial hypertension (AH) is very common, reaching according to various authors 70%, with accompanying psychoemotional disorders aggravate the course of sexual as well as somatic disorders. Associated pathology increases the risk of premature death, worsens the prognosis and reduced social functioning of patients. The common pathogenetic mechanisms of ED, anxiety and depressive disorders and hypertension are endothelial dysfunction with decreased nitric oxide, low levels of androgens, the violation of cortico-visceral connections with the imbalance of the hypothalamic-pituitary-adrenal system and sympathicotonia. Complex pathophysiology requires prescription of adequate anti-hypertensive and psychotherapy, effective treatment of erectile dysfunction.

Keywords: 
erectile dysfunction
anxiety and depressive disorders
arterial hypertension
pathogenetic relationship
Phosphodiesterase type 5 inhibitors
adaptogens



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction // Am. J. Cardiol. 2000; 86 (2): 41–5.
  2. El-Sakka A. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two? // J. Sex Med. – 2011; 8 (4): 937–40.
  3. Hatzimouratidis K., Eardley I., Giuliano F. et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology Web site. http://uroweb.org/guideline/male-sexual-dysfunction/ Updated 2015.
  4. Lewis R., Fugl-Meyer K., Corona G. et al. Definitions / epidemiology / risk factors for sexual dysfunction // J. Sex Med. – 2010; 7: 1598–607.
  5. Pushkar' D.Ju., Kamalov A.A., Al'-Shukri S.H. i dr. Pervoe pilotnoe epidemiologicheskoe issledovanie rasprostranennosti erektil'noj disfunktsii v Rossijskoj Federatsii. Effektivnaja farmakoterapija // Endokrinologija. – 2013; 1 (9): 28–31.
  6. Laumann E. et al. Sexual dysfunction in the United States: Prevalence and predictors // JAMA. – 1999; 281: 537–44.
  7. Smith D., Frankel S., Yamell J. Sex and death: are they related? Findings from the Caerphilly Cohort Study // BMJ. – 1997; 315: 1641–4.
  8. Bach L., Mortimer J., Van de Weerd C. et al. The association of physical and mental health with sexual activity in older adults in a retirement community // J. Sex Med. – 2013; 10 (11): 2671–8.
  9. Gandaglia G., Briganti A., Jackson G. et al. A systematic review of the association between erectile dysfunction and cardiovascular disease // Eur. Urol. – 2014; 65: 968–78.
  10. Giuliano F., Leriche A., Jaudinot E. et al. Prevallence of erectile dysfunction among 7689 patients with diabbetes or hypertension, or both // J. Urol. – 2004; 64: 1196–201.
  11. Vlachopoulos C. Definition and Assessment of Erectile Dysfunction. In: M. Viigimaa, C. Vlachopoulos, M.Doumas. Erectile Dysfunction in Hypertension and Cardiovascular Disease / Springer International Publishing, Switzerland, 2015; pp. 9–17.
  12. Clavijo R., Miner M., Rajfer J. Erectile Dysfunction and Essential Hypertension: The Same Aging-related Disorder? // Rev. Urol. – 2014; 16: 167–71.
  13. Blick C., Ritchie R., Sullivan M. Is Erectile Dysfunction an Example of Abnormal Endothelial Function? // Curr. Vasc. Pharmacol. – 2016; 14 (2): 163–7.
  14. La Vignera S., Condorelli R., Vicari E. et al. Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction // J. Endocrinol. Invest. – 2011; 34 (10): 314–20.
  15. Arana Rosainz Mde J., Ojeda M., Acosta J. et al. Imbalanced lowgrade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction // J. Sex Med. – 2011; 8: 2017–30.
  16. Montorsi P., Montorsi F., Schulman C. Is erectile dysfuncttion the «tip of the iceberg» of a systemic vascular disorder? // Eur. Urol. – 2003; 44: 352–4.
  17. Vlachopoulos C., Ioakeimidis N, Terentes-Printzios D. et al. Plasma total testosterone and incident cardiovascular events in hypertensive patients // Am. J. Hypertens. – 2013; 26: 373–81.
  18. Novo S., Iacona R., Bonomo V. et al. Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men according to the Framingham risk score // Atherosclerosis. – 2015; 238 (2): 415–9.
  19. Spitzer M., Basaria S, Travison T. et al. The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial // Andrology. – 2013; 1 (3): 475–82.
  20. Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men // Aging Male. – 2015; 18 (1): 5–15.
  21. Dean J., McMahon C., Guay A. et al. The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men // J. Sex Med. – 2015; 12 (8): 1660–86.
  22. Gathright E., Goldstein C., Josephson R. et al. Depression increases the risk of mortality in patients with heart failure: A meta-analysis // J. Psychosom. Res. – 2017; 94: 82–9.
  23. Scalco A., Scalco M., Azul J. et al. Hypertension and depression // Clinics. – 2005; 60 (3): 241–50.
  24. Nuralieva N.F., Napalkov D.A. Depressija i kardiovaskuljarnye bolezni // Vestn. RAMN. – 2014; 9–10: 21–6.
  25. Fiedorowicz J. Depression and cardiovascular disease: an update on how course of illness may influence risk // Curr. Psychiatry Rep. – 2014; 16 (10): 492.
  26. Finnell J., Wood S. Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress // Neurobiol. Stress. – 2016; 4: 1–14.
  27. Atlantis E., Shi Z., Penninx B. et al. Chronic medical conditions mediate the association between depression and cardiovascular disease mortality // Soc. Psychiatry Psychiatr. Epidemiol. – 2012; 47 (4): 615–25.
  28. Berntson J., Stewart K., Vrany E. et al. Depressive symptoms and self-reported adherence to medical recommendations to prevent cardiovascular disease: NHANES 2005–2010 // Soc. Sci. Med. – 2015; 138: 74–81.
  29. Piepoli M., Hoes A., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) // Eur. Heart J. – 2016; 37 (29): 2315–81.
  30. Mamedov M.N. Problemy muzhskogo zdorov'ja v kardiologicheskoj praktike. 2 izd. / M.: Kardioprogress, 2014.
  31. Chrysant S. Antihypertensive therapy causes erectile dysfunction // Curr. Opin. Cardiol. – 2015; 30 (4): 383–90.
  32. Al Khaja K., Sequeira R., Alkhaja A. et al. Antihypertensive Drugs and Male Sexual Dysfunction: A Review of Adult Hypertension Guideline Recommendations // J. Cardiovasc. Pharmacol. Ther. – 2016; 21 (3): 233–44.
  33. DeLay K., Haney N., Hellstrom W. Modifying Risk Factors in the Management of Erectile Dysfunction: A Review // World J. Mens Health. – 2016; 34 (2): 89–100.
  34. Nehra A., Jackson G., Miner M. et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease // Mayo Clin. Proc. – 2012; 87: 766–78.
  35. Yuan J., Zhang R., Yang Z. et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis // Eur. Urol. – 2013; 63: 902.
  36. Kalinchenko S.Ju., Tjuzikov I.A., Vorslov L.O. i dr. Erektil'naja disfunktsija: paradoksy i paradigmy sovremennoj patogeneticheskoj farmakoterapii // Sonsilium Medicum. – 2014; 16 (1): 78–82.
  37. Petrova E.V., Vakina T.N. Terapevticheskaja korrektsija urovnja degidroepiandrosterona-sul'fata i testosterona pri seksual'nyh disfunktsijah // Vrach. – 2014; 1: 60–1.
  38. Petrova E.V., Vakina T.N., Burmistrova L.A. Seksual'nye disfunktsii pri trevozhno-depressivnyh rasstrojstvah // Lechaschij vrach. – 2014; 5: 108–11.
  39. Petrova E., Shutov A. Therapeutic correction testosterone deficiency in hypertensive men with erectile dysfunction and depression // J. Sex Med. – 2016; 13 (5, Suppl. 2): 146.